Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.
U.K. Market Performance
7D7 Days: 0.7%
3M3 Months: 7.0%
1Y1 Year: 6.3%
YTDYear to Date: 8.3%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 4.5% in that time. As for the longer term, the market has risen 6.3% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...